Prevalence of Monoclonal Gammopathy of Undetermined Significance/Myeloma in Patients with Acute Osteoporotic Vertebral Fractures
T. Golombick,T. Diamond
DOI: https://doi.org/10.1159/000162282
2008-10-14
Acta Haematologica
Abstract:In this retrospective, cross-sectional, observational study, we determined the prevalence of MGUS/myeloma in patients presenting with acute osteoporotic vertebral fractures over 18 months. We investigated 134 consecutive patients referred to the Endocrine Department at St George Hospital with acute osteoporotic vertebral fractures between July 2005 and December 2006. We collected the following data: clinical demographics (age, sex, smoking history, alcohol intake, diagnostic diseases and medications), serum biochemistry (calcium, 25-hydroxyvitamin D, parathyroid hormone), protein electrophoresis, markers of bone resorption (urinary deoxypyridinoline, u-DPYD), spinal radiography and bone densitometry (dual-energy X-ray absorptiometry and quantitative computed tomography). All patients with a paraprotein underwent bone biopsy to determine the percentage of plasma cells in the bone marrow. Patients were grouped according to the underlying cause of their osteoporosis, i.e. primary postmenopausal, glucocorticoid-induced (prednisone therapy 1 5 mg/day for longer than 3 months), MGUS, multiple myeloma and ‘other disorders’ (see below). After giving informed consent, all patients underwent venous blood collection for biochemical studies. Serum calcium, electrolytes and liver functions were measured using standard auto-analyzer methods, serum 25-hydroxyvitamin D by radioimmunoassay (Diasorin, Stillwater, Mich., USA) and serum parathyroid hormone by an immunoradiometric assay (Nichols Institute, San CleMonoclonal gammopathy of undetermined significance (MGUS) is the most common of the monoclonal gammopathies. MGUS is typified by a serum M protein value of ! 30 g/l, fewer than 10% plasma cells in the bone marrow, no or a small amount of M protein in the urine and the absence of lytic bone lesions, anemia, hypercalcemia or renal insufficiency related to the plasma cell proliferative process [1] . In a report from the Mayo Clinic, it was found that almost 60% of patients with a monoclonal gammopathy have MGUS [1] . Multiple myeloma can be preceded by MGUS. Myeloma is a progressive neoplastic disease and is often associated with multiple osteolytic lesions, hypercalcemia, anemia, renal damage and increased susceptibility to bacterial infections. Fractures are common in myeloma as a result of lytic bone lesions, generalized bone loss and elevated bone turnover. Whilst MGUS is largely considered a benign condition, a number of studies show that patients with MGUS are at increased risk of developing fractures even before progression to myeloma [2] . Elevated bone turnover is an independent predictor of fracture risk, and a number of studies have demonstrated elevated bone resorption and/or reduced bone formation among patients with MGUS and myeloma [3, 4] . A study by Diamond et al. [5] found that in a small series of 18 MGUS patients, bone density was substantially reduced at the hip and spine compared with normal values in young persons. In a retrospective cohort study, Melton et al. [2] found that the risk of vertebral, but not peripheral, fractures is increased among MGUS patients. Received: April 10, 2008 Accepted after revision: July 7, 2008 Published online: October 14, 2008